Pulmonary Drugs Market Report 2025

The pulmonary drugs market size has grown steadily in recent years. It will grow from $54.28 billion in 2024 to $56.98 billion in 2025 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to the rise in the prevalence of respiratory diseases, the increase in smoking rates, the growth in the geriatric population, the expansion of healthcare access, and the surge in pollution levels.

The pulmonary drugs market size is expected to see strong growth in the next few years. It will grow to $70.35 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to growing healthcare infrastructure, rising prevalence of cardiovascular disease, expanding homecare treatments, rising awareness about pulmonary diseases, and rising prevalence of asthma. Major trends in the forecast period include technological advancements, AI-driven drug discovery, smart inhaler adoption, nanotechnology-based formulations, and gene therapy developments.

The forecast of 5.4% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. respiratory clinics by inflating prices of long-acting bronchodilators and mucolytic agents manufactured in Spain and India, resulting in reduced chronic obstructive pulmonary disease management options and higher pulmonary care expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of respiratory diseases is expected to drive the expansion of the pulmonary drugs market. Respiratory disorders are medical conditions that affect the lungs and airways, hindering normal breathing and oxygen exchange. The incidence of respiratory disorders is rising due to factors such as smoking, which contributes to lung damage and chronic diseases. Pulmonary drugs are vital in managing these conditions by improving lung function, reducing inflammation, and alleviating airway obstruction, thus enhancing breathing. For example, in November 2023, the Bureau of Labor Statistics, a U.S.-based government agency, reported that the illness rate among private industry employers in 2022 rose to 45.2 cases per 10,000 full-time equivalent (FTE) workers, up from 37.7 cases in 2021. This increase was primarily due to a higher incidence of respiratory illnesses, which grew from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. As a result, the rising prevalence of respiratory diseases is fueling the growth of the pulmonary drugs market.

Leading companies in the pulmonary drugs market are focusing on developing innovative treatments, such as single-inhaler triple therapy (SITT), to improve treatment effectiveness, enhance patient adherence, and simplify medication regimens for better disease management. Single-inhaler triple therapy combines three different medications into one inhaler to more effectively manage chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD). For example, in April 2022, GlaxoSmithKline Pharmaceuticals Limited, an India-based pharmaceutical company, introduced Trelegy Ellipta, India's first single-inhaler triple therapy for COPD patients. This therapy combines fluticasone furoate, umeclidinium, and vilanterol to improve lung function and reduce symptom flare-ups. The innovative Ellipta inhaler ensures accurate dosing and enhances patient adherence compared to multiple-inhaler therapies. With over 100 million COPD patients in India, this launch aims to simplify treatment and improve patient outcomes.

In September 2024, Roivant Sciences Ltd., a U.S.-based biotechnology company, acquired a pulmonary hypertension drug from Bayer AG for an undisclosed sum. This acquisition enables Roivant to expand its respiratory portfolio and advance innovative treatments for pulmonary hypertension, thus improving patient outcomes and addressing unmet medical needs. Bayer AG, a Germany-based company, manufactures pulmonary drugs, including treatments for respiratory conditions such as pulmonary hypertension.

Major players in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, and Circassia Pharmaceuticals plc.

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pulmonary drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pulmonary drugs market consists of the sales of inhalers, nebulizers, bronchodilators, anti-inflammatory agents, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The pulmonary drugs market research report is one of a series of new reports that provides pulmonary drugs market statistics, including the pulmonary drugs industry global market size, regional shares, competitors with the pulmonary drugs market share, detailed pulmonary drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the pulmonary drugs industry. This pulmonary drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Pulmonary drugs are medications designed to target the respiratory system to enhance lung function, reduce inflammation, and manage airway disorders. They are commonly used to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and other respiratory illnesses.

The main classes of pulmonary drugs include inhaled corticosteroids, long-acting beta-2 agonists, antihistamines, vasodilators, short-acting beta-2 agonists, and others. Inhaled corticosteroids are anti-inflammatory medications delivered directly to the lungs via inhalers, helping to manage chronic respiratory conditions such as asthma and COPD by reducing airway inflammation and preventing flare-ups. These drugs are used for indications such as asthma, COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and more. They are distributed through various channels, including retail pharmacies, online pharmacies, and hospital pharmacies.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.